Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics.
Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics.
复制标题
DOI：
10.3389/fimmu.2021.752227
复制
发表时间：
2021
影响因子：
7.3
通讯作者：
Brunotte L
中科院分区：
文献类型：
--
作者：
Kumar S;Çalışkan DM;Janowski J;Faist A;Conrad BCG;Lange J;Ludwig S;Brunotte L
自2019年11月以来，SARS-CoV-2大流行已在全球造成近2亿人感染，400多万人死亡（截至2021年8月2日，世界卫生组织的最新信息）。大流行仅一年内，就设计了多种疫苗并获得批准用于世界人口的免疫接种。在疫苗接种率高的国家，如以色列和英国，生产的疫苗具有显著的保护作用。然而，有限的生产能力、不良的分销基础设施和政治上的犹豫仍然妨碍许多国家提供疫苗。此外，由于SARS-CoV-2变种对疫苗具有免疫逃逸特性，全球新感染人数以及发展为严重COVID-19的患者人数仍然很高。新的研究报告说，约8%的感染者出现长期症状，在私人和专业层面上受到强烈的个人限制，这导致了这种流行病造成的长期社会经济问题。直到今天，紧急使用批准的COVID-19治疗选择仅限于抗病毒的Remdesivir，一种靶向病毒聚合酶的核苷类似物，糖皮质类固醇地塞米松以及中和抗体。这些治疗方法的治疗益处正在进行辩论，评估这些治疗方法有效性的临床研究仍在进行中。为识别新冠肺炎的新治疗方法，目前及到后疫情时代，世界各地的公司及科研团队正对多种实验方法进行科学评估。为了加速有前途的候选药物的临床转化，专门培养了已知批准药物的再利用方法，但也正在开发和研究新技术。本文综述了实验室工作台的最新进展以及新兴治疗候选药物的临床状况，并讨论了SARS-CoV-2生物学和COVID-19临床过程治疗策略的可能治疗切入点。
Since November 2019 the SARS-CoV-2 pandemic has caused nearly 200 million infection and more than 4 million deaths globally (Updated information from the World Health Organization, as on 2nd Aug 2021). Within only one year into the pandemic, several vaccines were designed and reached approval for the immunization of the world population. The remarkable protective effects of the manufactured vaccines are demonstrated in countries with high vaccination rates, such as Israel and UK. However, limited production capacities, poor distribution infrastructures and political hesitations still hamper the availability of vaccines in many countries. In addition, due to the emergency of SARS-CoV-2 variants with immune escape properties towards the vaccines the global numbers of new infections as well as patients developing severe COVID-19, remains high. New studies reported that about 8% of infected individuals develop long term symptoms with strong personal restrictions on private as well as professional level, which contributes to the long socioeconomic problems caused by this pandemic. Until today, emergency use-approved treatment options for COVID-19 are limited to the antiviral Remdesivir, a nucleoside analogue targeting the viral polymerase, the glucocorticosteroide Dexamethasone as well as neutralizing antibodies. The therapeutic benefits of these treatments are under ongoing debate and clinical studies assessing the efficiency of these treatments are still underway. To identify new therapeutic treatments for COVID-19, now and by the post-pandemic era, diverse experimental approaches are under scientific evaluation in companies and scientific research teams all over the world. To accelerate clinical translation of promising candidates, repurposing approaches of known approved drugs are specifically fostered but also novel technologies are being developed and are under investigation. This review summarizes the recent developments from the lab bench as well as the clinical status of emerging therapeutic candidates and discusses possible therapeutic entry points for the treatment strategies with regard to the biology of SARS-CoV-2 and the clinical course of COVID-19.
登录
查看更多内容
影响因子：
5.6
作者：
Blaess M;Kaiser L;Sommerfeld O;Csuk R;Deigner HP
通讯作者：
Deigner HP
DOI：
10.1016/j.mjafi.2020.08.004
发表时间：
2020-10-01
期刊：
Medical journal, Armed Forces India
影响因子：
--
作者：
Agrawal, Umang;Raju, Reyma;Udwadia, Zarir F
通讯作者：
Udwadia, Zarir F
影响因子：
64.5
作者：
Bouhaddou, Mehdi;Memon, Danish;Krogan, Nevan J.
通讯作者：
Krogan, Nevan J.
影响因子：
5.6
作者：
Baghaei P;Dastan F;Marjani M;Moniri A;Abtahian Z;Ghadimi S;Valizadeh M;Heshmatnia J;Sadat Mirenayat M;Abedini A;Kiani A;Eslaminejad A;MohammadReza Hashemian S;Jamaati H;Zali A;Akbar Velayati A;Tabarsi P
通讯作者：
Tabarsi P
Tocilizumab对多节幼年特发性关节炎患者的疗效和安全性：第3期，随机，双盲戒断试验的结果。
影响因子：
27.4
作者：
Brunner HI;Ruperto N;Zuber Z;Keane C;Harari O;Kenwright A;Lu P;Cuttica R;Keltsev V;Xavier RM;Calvo I;Nikishina I;Rubio-Pérez N;Alexeeva E;Chasnyk V;Horneff G;Opoka-Winiarska V;Quartier P;Silva CA;Silverman E;Spindler A;Baildam E;Gámir ML;Martin A;Rietschel C;Siri D;Smolewska E;Lovell D;Martini A;De Benedetti F;Paediatric Rheumatology International Trials Organisation PRINTO;Pediatric Rheumatology Collaborative Study Group (PRCSG)
通讯作者：
Pediatric Rheumatology Collaborative Study Group (PRCSG)